In one paragraphArticle in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Andrew FrauenpreisLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA 90502, USA.ORCID 0009-0002-2986-0103 Soumyaroop BhattacharyaCenter for Children's Health Research, University of Rochester Medical Center, Rochester, NY 14642, USA.ORCID 0000-0003-1140-7845 Randa BelgacemiLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA 90502, USA.
Pauline SokolskiyLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA 90502, USA.
Gail DeutschDepartment of Laboratory Medicine and Pathology, Seattle Children's Research Institute, Seattle, WA 98101, USA.
Nicholas JendzjowskyLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA 90502, USA.ORCID 0000-0002-4342-1839 Ian A GlassDepartment of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195, USA.ORCID 0000-0001-6762-8407 Thomas J MarianiCenter for Children's Health Research, University of Rochester Medical Center, Rochester, NY 14642, USA.
Denise Al AlamLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA 90502, USA.ORCID 0000-0003-3148-7352 Soula DanopoulosLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA 90502, USA.
Funding
LABORATORY OF DEVELOPMENTAL BIOLOGYR24HD000836 · NICHD · UNIVERSITY OF WASHINGTON · PI Ian Amos Glass · 1995 to 2026
$16.9MType I IFN signaling during lung development in Down Syndrome-Multiome sequencing of human fetal and pediatric trisomy 21 lungsR01HL155104 · NHLBI · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI DANOPOULOS, SOULA ATHANASIA · 2021 to 2025
$3.3MMechanisms controlling early human lung developmentR01HL141856 · NHLBI · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI AL-ALAM, DENISE · 2018 to 2022
$2.5MCellular Senescence in Trisomy 21 lung diseaseR01HL171915 · NHLBI · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI Denise Al Alam, Christina Maria Pabelick · 2024 to 2026
$1.8MType I interferon regulates angiogenesis in Down Syndrome SupplementR21HL165411 · NHLBI · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI AL-ALAM, DENISE, DANOPOULOS, SOULA ATHANASIA · 2022 to 2023
$507kNHLBI NIH HHS R01 HL141856NHLBI NIH HHS R01 HL155104NHLBI NIH HHS R01 HL171915NHLBI NIH HHS R21 HL165411NICHD NIH HHS R24 HD000836NIH/NHLBI R21HL165411NIH/NHLBI Office of The Director, National Institutes of Health (OD) R01HL155104NIH/NICHD R24HD000836
6 · The paper itselfAbstract
Respiratory tract infections (RTIs) are amongst the leading causes of hospitalizations in children with Down syndrome (DS). Their elevated susceptibility likely stems from structural differences in the airways and immune system abnormalities. The aim of this study was to characterize immune cells in prenatal Trisomy 21 (T21) lungs, potentially explaining vulnerability to RTIs. Single-cell RNA sequencing was used to profile immune cells in prenatal T21 (
Indexed as
Down SyndromeLungB-LymphocytesFemaleHumansPregnancyB cellsDown syndrometranscriptomics
Identifiers
PMID41369355
PMCPMC12691487
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390